An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

April 27, 2028

Study Completion Date

April 27, 2028

Conditions

CRC, Colorectal Cancer

Interventions

DRUG

Tunlametinib combined with Fruquintinib

All Listed Sponsors

lead

Liu Huang

OTHER